한국어
Quantus

Kookjeon Pharmaceutical

307750 · KOSDAQ
₩2,340+2.63%
2026-09-04 close

Kookjeon Pharmaceutical last closed at ₩2,340 (+2.63%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

C
Overall: 건강관리 213/291 · top 73%
Factor composite · relative position in sector

PER 67.63 · PBR 1.21 — own-history percentile 71/100 · 78/100

Open self-history band
PER71/100
PBR78/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart2022: 10원20222023: No dividend paid2024: 10원2025: 10원10원2025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
D
Growth
C+
Yield
F
Safety
C
Reference indicatorView observed cut rates

Paid 2 consecutive years · Raised 0 consecutive years · Yield 0.43% (based on 2025 payment of 10원) · 3-year growth +0.0%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Grey zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 1.80
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
1.80
Beneish M-Score
-2.47

No statistical flag

Sloan accrual
-3.91%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

6/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score6/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업이익률 악화 (5.3% → -1.7%, -7.0%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 247% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 90 of 287, share 0.2%.

90 / 2870.2%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6국전0.2%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-1.7%
Interest coverage
-0.3x
Return on equity (ROE)
1.8%

Operating margin −5pp

Operating loss
Interest coverageBase -0.3x adverse case -1.1x
Return on equity (ROE)Base 1.8% adverse case -17.8%

Revenue −15%

Interest coverage risk
Interest coverageBase -0.3x adverse case -0.2x
Return on equity (ROE)Base 1.8% adverse case -10.5%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -0.3x adverse case -0.2x
Return on equity (ROE)Base 1.8% adverse case -13.2%

Interest coverage limit

Already below the limit by 7.7pp

Interest coverage limit at an operating margin of 6%

Interest expense coverage threshold

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 홍종호52.23%2026-07-24 · 증감 0.00%p

Connections

AI-extracted related companies · for reference

🔗 See in the full market map →

Recent filings

Kookjeon Pharmaceutical's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About Kookjeon Pharmaceutical
What technical signals does Kookjeon Pharmaceutical (307750) have?
Kookjeon Pharmaceutical current technical signals: no active technical signal.
Is Kookjeon Pharmaceutical a cup-and-handle pattern?
No. Kookjeon Pharmaceutical has no valid cup-and-handle signal right now.
What are Kookjeon Pharmaceutical's financials and valuation?
Kookjeon Pharmaceutical's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy